IDH1 Antibody / Isocitrate Dehydrogenase

NSJ Bioreagents
Product Code: NSJ-V2609IHC
Product Group: Primary Antibodies
Supplier: NSJ Bioreagents
CodeSizePrice
NSJ-V2609IHC-7ML7 ml£534.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: Mouse IgG1 kappa
Antibody Clonality: Monoclonal
Antibody Clone: IDH1/1152
Regulatory Status: RUO
Target Species: Human
Application: Immunohistochemistry- Paraffin Embedded (IHC-P)
Storage:
Store the IDH1 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Images

1 / 2
IHC: Formalin-fixed, paraffin-embedded human colon carcinoma stained with IDH1 antibody (clone IDH1/1152).~
2 / 2
IHC: Formalin-fixed, paraffin-embedded human prostate carcinoma stained with IDH1 antibody (clone IDH1/1152).

IHC: Formalin-fixed, paraffin-embedded human colon carcinoma stained with IDH1 antibody (clone IDH1/1152).~
IHC: Formalin-fixed, paraffin-embedded human prostate carcinoma stained with IDH1 antibody (clone IDH1/1152).

Documents

Further Information

Application Details:
The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Application Note:
Optimal dilution of the IDH1 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0 or 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Description:
It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming a-ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of a-ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
Format:
Purified
Formulation:
Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*
Immunogen:
A recombinant fragment (119 amino acid residues around aa 280-420) from the human protein was used as the immunogen for the IDH1 antibody.
Limitation:
This IDH1 antibody is available for research use only.
Localization:
Cytoplasmic & nuclear
Purity:
Protein G affinity chromatography
Uniprot #:
O75874